A Nottingham regenerative medicine company which has developed a groundbreaking therapy that can help prevent sight loss has completed a £500,000 funding round backed by Mercia Fund Managers, angel investors and the University of Nottingham.

The investment will allow NuVision Biotherapies to further develop its product range, strengthen its management team and increase sales in the UK and internationally.